MedTrace Logo

Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study)

NCT01266187 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-09-22

No results posted yet for this study

Summary

Is a perioperative chemotherapy based on FOLFOX and Cetuximab (K-RAS wild-type) associated with a higher rate of postoperative complications in patients with resectable colorectal liver metastases as compared to only adjuvant FOLFOX and chemotherapy? Are there any differences for disease free survival between periand postoperative treatment in patients with \>3 liver metastases or at least one metastasis \> or = 5 cm in diameter?

Conditions

  • Liver Metastasis

Interventions

PROCEDURE

adjuvant surgery + FOLFOX + cetuximab

surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab

PROCEDURE

perioperative/Folfox + cetuximab

12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery -\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Ulf P Neumann, Prof. · RWTH Aachen University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266187 on ClinicalTrials.gov